NRC FORM 374 PAGE 1 OF 4 PAGES U.S. NUCLEAR REGULATORY COMMISSION Amendment No. 62 MATERIALS LICENSE Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below. Licensee In accordance with letter dated 4. Expiration Date: June 30, 2024 October 22, 2021, 1. Community Howard Regional Health, Inc. **R REG** 5. Docket No.: 030-13342 2. 3500 S LaFountain St. 3. License No.: 13-13028-02 is Reference No.: 030-38264/13-32789-01 Kokomo, IN 46902 amended in its entirety to read as follows: 6. Byproduct, source, 7. Chemical and/or physical form Maximum amount that licensee 9. Authorized use 8. and/or special nuclear may possess at any one time material under this license A. Any byproduct material A. As Needed A. For use in uptake, dilution and A. Anv permitted by 10 CFR excretion studies permitted by 10 CFR HINN W 35.100 35.100. Β. As Needed B. Any byproduct material B. For use in imaging and localization B. Any studies permitted by 10 CFR 35.200. permitted by 10 CFR 35.200 2 curies tota C. For any use permitted by 10 CFR C. Any byproduct material C. Anv permitted by 10 CFR 35.300. 35.300

NRC FORM 374A	U.S. NUCLEAR REGULATORY	COMMISSION	PAGE 2 OF 4 PAGES			
	License No.: 13-13028-02	Docket or Reference N 030-13342 030-3	lo.: 38264/13-32789-01			
MATERIALS LICENSE SUPPLEMENTARY SHEET	Amendment No. 62	000-10042 000-0	58204/13-32789-01			
10. A. Licensed material shall be used o	CONDITIONS		. Kokomo, Indiana.			
B. Licensed material listed in Subiter facilities located at 3503 S Reed F	n No. 6.B., limited to technetium-99m					
11. The Radiation Safety Officer (RSO) for this license is Edward E. Wroblewski, M.A., DABSNM.						
12. Licensed material shall only be used b	by, or under the supervision of:	CC CC				
A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.						
B. The following individuals are authorized User (M.D.,D.O.,etc.)	orized users for the material and medi Material and Use	cal uses as indicated:				
Mark Allen, M.D.	10 CFR 35.100,10 CFR 35.200	; 10 CFR 35.300 (limited to th	ne oral administration of sodium			
Ibad U. Ansari, M.D. Mary Ellen Below, M.D.	iodide I-131) 10 CFR 35.100,10 CFR 35.200 10 CFR 35,100,10 CFR 35.200					
James Blahunka, M.D.	10 CFR 35.100,10 CFR 35.200					
James R. Bognanno, M.D.	10 CFR 35.100,10 CFR 35.200					
Gitasree Borthakur, M.D.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)					
Gregory A. Bosh, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)					
Kevin E. Burton, M.D.	10 CFR 35.100,10 CFR 35.200	,				
Justin P. Chang, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)					
Stefan Andrew Hoff, M.D.	10 CFR 35.100,10 CFR 35.200 iodide I-131)	; 10 CFR 35.300 (limited to th	ne oral administration of sodium			

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	AISSION PAGE 3 OF 4 PAGES			
	License No.: 13-13028-02 Docket or Reference No.:				
MATERIALS LICENSE		030-13342 030-38264/13-32789-01			
SUPPLEMENTARY SHEET	Amendment No. 62				
Authorized User (M.D.,D.O.,etc.)	Material and Use				
Tarun R. Jindal, M.D.		CFR 35.300 (limited to the oral administration of sodium			
Habib Komari, M.D.	iodide I-131) R REGUL	1			
Kenyon K. Kopecky, M.D.	10 CFR 35.100,10 CFR 35.200,10 C	CFR 35.300			
David Kurlander, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300				
Michael L. Lutz, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300				
Rajesh Mallela, M.D.	10 CFR 35.200				
Gregory A. Merchun, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 25.200,10 CFR 25.200,100,100,100,100,100,100,100,100,100,	CFR 35.300			
Thomas N. Murphy, M.D.	10 CFR 35.100,10 CFR 35.200	0			
Mark Joseph Paluszny, M.D.	- 10 CFR 35.100,10 CFR 35.200				
Marc J. Pinchouck, M.D.	10 CFR 35.100,10 CFR 35.200				
Anil K. Ranginani, M.D.	10 CFR 35.100,10 CFR 35.200				
Paul W. Sheets, M.D.	10 CFR 35.100,10 CFR 35.200				
Deoyrat Singh, M.D.	10 CFR 35.200	Sec. 1			
Mark Allan Sparrow, M.D.	10 CFR 35.300 (limited to the oral a	dministration of sodium iodide I-131)			
Stephan M. Stockberger, Jr., M.D.	10 CFR 35.100,10 CFR 35.200; 10 iodide I-131)	CFR 35.300 (limited to the oral administration of sodium			
Michael L. Swack, M.D.	10 CFR 35.100,10 CFR 35.200				
Perry E. Wethington, M.D.	10 CFR 35.100,10 CFR 35.200				

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION PAGE 4 OF 4 PAGES			
	License No.: 13-13028-02	Docket or Reference No.:		
MATERIALS LICENSE		030-13342	030-38264/13-32789-01	
SUPPLEMENTARY SHEET	Amendment No. 62			

- 13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
  - A. Letter dated December 16, 2013 (ML14023A635)
  - B. Letter dated September 24, 2015 (ML15288A522)
  - C. Letter dated May 9, 2016 (ML16139A407)
  - D. Letter dated June 28, 2016 (ML16181A197)
  - E. Letter dated April 13, 2017 (ML17103A558)
  - F. Letter dated April 11, 2019 (ML19106A220)
  - G. Letter dated May 29, 2019 (ML19154A096)

## FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 5, 2022

By:

Magdalena R. Gryglak Region 3